Twenty years of systemic therapy for breast cancer

Lida Mina, George W. Sledge

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The past 2 decades of systemic therapy for breast cancer have been a period of monumental change, in terms of both theory and technology. Adjuvant therapy developed from two strands of research - one in systemic chemotherapy and one in hormonal therapy - both of which were aided by the application of higher statistical methodology to clinical trials. The agent with the single greatest public health impact in oncology has been tamoxifen, but problems with tamoxifen therapy led to the development of the aromatase inhibitors, and further research led to the use of hormonal therapy in a chemopreventive capacity. The evolution of systemic chemotherapy for breast cancer has been an interplay between theory-driven approaches and new agents. By the late 1980s, accumulating data revealed that overexpression of HER2 (erbB2) played an important role in a substantial portion of breast cancers, which prompted the development of trastuzumab (Herceptin), an agent targeting HER2-positive disease. Determining HER2 status proved essential to assessing patient eligibility for trastuzumab therapy. Decoding of the human genome and application of bioinformatics further revolutionized the possibilities in breast cancer treatment.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalOncology (Williston Park, N.Y.)
Volume20
Issue number1
StatePublished - 2006

Fingerprint

Breast Neoplasms
Tamoxifen
Therapeutics
Drug Therapy
Aromatase Inhibitors
Human Genome
Computational Biology
Research
Public Health
Clinical Trials
Technology
Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

Twenty years of systemic therapy for breast cancer. / Mina, Lida; Sledge, George W.

In: Oncology (Williston Park, N.Y.), Vol. 20, No. 1, 2006, p. 25-32.

Research output: Contribution to journalArticle

Mina, L & Sledge, GW 2006, 'Twenty years of systemic therapy for breast cancer', Oncology (Williston Park, N.Y.), vol. 20, no. 1, pp. 25-32.
Mina, Lida ; Sledge, George W. / Twenty years of systemic therapy for breast cancer. In: Oncology (Williston Park, N.Y.). 2006 ; Vol. 20, No. 1. pp. 25-32.
@article{834a50e846ac414abd2ee11c42dd0fd4,
title = "Twenty years of systemic therapy for breast cancer",
abstract = "The past 2 decades of systemic therapy for breast cancer have been a period of monumental change, in terms of both theory and technology. Adjuvant therapy developed from two strands of research - one in systemic chemotherapy and one in hormonal therapy - both of which were aided by the application of higher statistical methodology to clinical trials. The agent with the single greatest public health impact in oncology has been tamoxifen, but problems with tamoxifen therapy led to the development of the aromatase inhibitors, and further research led to the use of hormonal therapy in a chemopreventive capacity. The evolution of systemic chemotherapy for breast cancer has been an interplay between theory-driven approaches and new agents. By the late 1980s, accumulating data revealed that overexpression of HER2 (erbB2) played an important role in a substantial portion of breast cancers, which prompted the development of trastuzumab (Herceptin), an agent targeting HER2-positive disease. Determining HER2 status proved essential to assessing patient eligibility for trastuzumab therapy. Decoding of the human genome and application of bioinformatics further revolutionized the possibilities in breast cancer treatment.",
author = "Lida Mina and Sledge, {George W.}",
year = "2006",
language = "English",
volume = "20",
pages = "25--32",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Twenty years of systemic therapy for breast cancer

AU - Mina, Lida

AU - Sledge, George W.

PY - 2006

Y1 - 2006

N2 - The past 2 decades of systemic therapy for breast cancer have been a period of monumental change, in terms of both theory and technology. Adjuvant therapy developed from two strands of research - one in systemic chemotherapy and one in hormonal therapy - both of which were aided by the application of higher statistical methodology to clinical trials. The agent with the single greatest public health impact in oncology has been tamoxifen, but problems with tamoxifen therapy led to the development of the aromatase inhibitors, and further research led to the use of hormonal therapy in a chemopreventive capacity. The evolution of systemic chemotherapy for breast cancer has been an interplay between theory-driven approaches and new agents. By the late 1980s, accumulating data revealed that overexpression of HER2 (erbB2) played an important role in a substantial portion of breast cancers, which prompted the development of trastuzumab (Herceptin), an agent targeting HER2-positive disease. Determining HER2 status proved essential to assessing patient eligibility for trastuzumab therapy. Decoding of the human genome and application of bioinformatics further revolutionized the possibilities in breast cancer treatment.

AB - The past 2 decades of systemic therapy for breast cancer have been a period of monumental change, in terms of both theory and technology. Adjuvant therapy developed from two strands of research - one in systemic chemotherapy and one in hormonal therapy - both of which were aided by the application of higher statistical methodology to clinical trials. The agent with the single greatest public health impact in oncology has been tamoxifen, but problems with tamoxifen therapy led to the development of the aromatase inhibitors, and further research led to the use of hormonal therapy in a chemopreventive capacity. The evolution of systemic chemotherapy for breast cancer has been an interplay between theory-driven approaches and new agents. By the late 1980s, accumulating data revealed that overexpression of HER2 (erbB2) played an important role in a substantial portion of breast cancers, which prompted the development of trastuzumab (Herceptin), an agent targeting HER2-positive disease. Determining HER2 status proved essential to assessing patient eligibility for trastuzumab therapy. Decoding of the human genome and application of bioinformatics further revolutionized the possibilities in breast cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=33745926823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745926823&partnerID=8YFLogxK

M3 - Article

C2 - 16572592

AN - SCOPUS:33745926823

VL - 20

SP - 25

EP - 32

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -